Abstract The activation of IFITM3 may be a potential new target for treating sepsis-associated encephalopathy (SAE), and it may be one of the key anti-apoptotic mechanisms in rhBNP exerting its therapeutic effect, providing new insight into the clinical treatment of SAE patients.
Introduction Sepsis-associated encephalopathy (SAE) is a frequent and debilitating complication of sepsis, characterized by long-term cognitive impairment and mental health disorders. Previous research established that recombinant human brain natriuretic peptide (rhBNP) can mitigate brain damage in septic models, but the specific molecular pathways involved remained elusive. This study identifies Interferon-induced transmembrane protein 3 (IFITM3) as a critical mediator of hippocampal injury and a primary target for the neuroprotective effects of rhBNP.
Methods To investigate SAE, researchers utilized a cecal ligation and puncture (CLP) mouse model. Targeted gene manipulation was achieved by injecting an adeno-associated virus (rAAV) into the hippocampal CA1 region to overexpress IFITM3. Cognitive and behavioral outcomes were measured using the Open Field Test (OFT), Elevated Plus Maze (EPM), and Contextual Fear Memory tests. Molecular analysis included Western Blotting for protein quantification, Immunohistochemistry (IHC) for cellular localization, and TUNEL staining to assess neuronal apoptosis.
Results Experimental results revealed a significant upregulation of IFITM3 in the hippocampus of septic mice. Immunohistochemical analysis demonstrated that IFITM3 expression is cell-specific, localizing within the plasma membrane and cytoplasm of astrocytes and neurons, while remaining absent in microglia.
A key finding was that rhBNP treatment effectively reduced the expression of IFITM3 in these cell populations. Quantitative analysis of co-localization parameters confirmed that rhBNP significantly attenuates the sepsis-induced increase of IFITM3 in astrocytes.
Crucially, the therapeutic benefits of rhBNP were completely abolished when IFITM3 was artificially overexpressed. Mice in this group exhibited severe memory deficits and high anxiety, mirroring the untreated septic group. Further investigation into the molecular mechanism showed that IFITM3 promotes cell death via pro-apoptotic pathways (increasing Caspase-3 and Caspase-8) rather than through standard inflammatory signaling.
Discussion This study reframes IFITM3 from its traditional role as an antiviral protein to a central "death trigger" in the septic brain. By demonstrating that rhBNP exerts its protective effects by downregulating IFITM3 and preventing apoptosis in the hippocampal CA1 region, the authors provide a specific molecular target for future SAE therapies. While the study focuses on the hippocampus and acknowledges the need for further exploration of the cGMP signaling link, the results offer a significant step toward clinical translation for septic patients.
Conclusion IFITM3 is a pivotal protein in the pathogenesis of SAE. Its modulation by rhBNP highlights a novel anti-apoptotic mechanism that could serve as a foundation for new therapeutic strategies in treating sepsis-induced cognitive decline.
Summary updated